β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal cancer models combined with mechanistic bioenergetic testing in a prospective healthy volunteer cohort.
PubMed 41794025 · doi:10.1016/j.cell.2026.02.004
What was done
Researchers evaluated the effect of the ketone metabolite β-hydroxybutyrate (BHB) on chimeric antigen receptor (CAR) T-cell function and metabolism across multiple preclinical cancer models. They examined underlying mechanisms including tricarboxylic acid (TCA) cycle activity, oxidative phosphorylation, cytokine production, and transcriptional/epigenetic alterations. Additionally, they administered BHB to a prospective cohort of healthy human volunteers to evaluate its impact on peripheral T-cell mitochondrial parameters.
What was found
The abstract reports no exact quantitative figures or effect sizes. Qualitatively, BHB supported TCA cycle activity, oxidative phosphorylation, and ATP generation in CAR T cells, which was associated with increased proliferation, cytokine production, and improved tumor control in preclinical models. In the healthy volunteer cohort, BHB administration increased peripheral T-cell oxygen consumption, mitochondrial membrane potential, and ATP production.
Why it matters
These findings identify BHB as a potential metabolic adjunct to augment CAR T-cell persistence and antitumor activity, pointing toward dietary or metabolite supplementation strategies to improve cell therapy efficacy.
Limits
The abstract does not disclose sample sizes, volunteer demographics, dosing regimens, or quantitative statistical values. Antitumor efficacy was evaluated exclusively in preclinical models, and human data were restricted to surrogate bioenergetic endpoints in healthy volunteers rather than clinical outcomes in cancer patients.
Cited by
- supports Beta-hydroxybutyrate plays a significant role in expanding CAR T-cells.
- supports Moffitt Cancer Center is investigating the combination of CAR T-cell therapy and ketone metabolic therapy.